Official UK procurement notice
FILGOTINIB (JYSELECA) Tablets [HOMECARE]
Authority: Northern Health and Social Care Trust (Central government)
What is being bought
Published requirement descriptionContract for supply of FILGOTINIB (JYSELECA) Tablets via HOMECARE for a period of up to 3 years
The lotProcurement structure
single lot · no lot value publishedLot #1Awarded
Procedure terms & legal framework
From the official record- Procedure method
- Direct award
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 20 May 2026, 16:43 BST
- Last source update
- 2 Jun 2026, 15:14 BST
- Authority reference
DAC165/0526PM- FTS notice number
2026/S 000-051980- Latest notice
- Contract details notice (UK7)
- Delivery area
- Official registry OCID
ocds-h6vhtk-069e16Find a Tender
- Why no open competition
- Single Suppliers Intellectual Property Exclusive Rights
- Published justification
Purchase of drugs which are subject to patent protection/ Sole MA Holder, where no reasonable alternative or substitute exists.
Section 41 schedule 5(5) of the PA2023 permits a direct award in the case of single supplier and permits the award if the following conditions are met in relations to the public contract -
(a)due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and
(b)there are no reasonable alternatives to those goods, services or works.
The product required is only commercially available from one supplier and no competition or alternative exists for this product.
The Northern Health and Social Care Trust requires the purchase of Filgotinib which is subject to patent protection / Sole MA Holder and consequently no reasonable alternative of substitute exists.
These essential medicines are required from this supplier to ensure continuity of patient care, specifically for homecare support.
The absence of competition is not the artificial narrowing of the parameters of the procurement.
How it was run
Official notice- Submission deadline
- —
Timeline
1 Jun 2026 → 2 Jun 2026 · 2 dates- Standstill ends147 days ago1 Jun 2026, 23:59 BST
- Notice published146 days ago2 Jun 2026, 15:14 BST
Notice history
4 events · 3 releases on Find a Tender · since 20 May 2026- Transparency notice published20 May 2026, 16:43 BSTUK5
- Contract award notice published20 May 2026, 16:47 BSTUK6
- Contract details notice published2 Jun 2026, 15:14 BSTUK7
- Contract signature expected2 Jun 2026, 23:59 BSTscheduled
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Sciensus Pharma Services Ltd2 Jun 2026 – 31 May 2029 | £140,000 | 20 May 2026 | Awarded |
Contracts
Contract 1 · Sciensus Pharma Services Ltd
- Signed
- 1 Jun 2026
- Value
- £140,000
- Period
- 2 Jun 2026 – 31 May 2029
- Status
- active
No agreed KPIs: Not applicable as contract value is less than £5 million
Contracting authority & participating public bodies
Bidders & participating suppliers
1 commercial party on the notice- SCIENSUS PHARMA SERVICES LIMITEDAwarded supplier
Official documents & specifications (3)
Official links; attachments are not copiedNotices published for this procedure
- Contract details notice Contract details notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Transparency notice Transparency notice on Find a Tender